2invest Past Earnings Performance

Past criteria checks 2/6

2invest's earnings have been declining at an average annual rate of -19%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 70.3% per year. 2invest's return on equity is 8.2%, and it has net margins of 65%.

Key information

-19.0%

Earnings growth rate

-19.0%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate70.3%
Return on equity8.2%
Net Margin65.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How 2invest makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:2INV Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 248500
31 Mar 248300
31 Dec 239200
30 Sep 236-300
30 Jun 232-800
31 Mar 233-1500
31 Dec 223-2100
30 Sep 223-2000
30 Jun 223-2000
31 Mar 222-1100
31 Dec 212-200
30 Sep 211-12-10
30 Jun 211-1200
31 Mar 2105600
31 Dec 2005500
30 Sep 20036-20
30 Jun 20036-10
31 Mar 201-440
31 Dec 190-3300
30 Sep 19-7-4-10
30 Jun 19-4-300
31 Mar 19-1-330
31 Dec 181-340
30 Sep 1812-2101
30 Jun 1810-3101
31 Mar 189-391
31 Dec 178-481
30 Sep 176-581
30 Jun 174-561
31 Mar 173-551
31 Dec 162-431
30 Sep 161-331
30 Jun 161-431
31 Mar 161-431
31 Dec 151-431
30 Sep 150-421
30 Jun 150-421
31 Mar 150-321
31 Dec 140-321
30 Sep 140-322
30 Jun 140-322
31 Mar 140-322
31 Dec 130-322

Quality Earnings: 2INV has a large one-off loss of €5.0M impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: 2INV became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2INV has become profitable over the past 5 years, growing earnings by -19% per year.

Accelerating Growth: 2INV has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 2INV has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 2INV's Return on Equity (8.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 15:06
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

2invest AG is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew Murray DarleyCavendish
Mark BrewerCavendish
Christian OrqueraFirst Berlin Equity Research GmbH